COVID-19 test kit developer Lucira Health files for a $115 million IPO

Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.

Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company's initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. Its LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. The company is pre-revenue.

The Emeryville, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol LHDX. Lucira Health filed confidentially on November 23, 2020. BofA Securities, William Blair and LifeSci Capital are the joint bookrunners on the deal. No pricing terms were disclosed.

The article COVID-19 test kit developer Lucira Health files for a $115 million IPO originally appeared on IPO investment manager Renaissance Capital's web site

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.